<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224599</url>
  </required_header>
  <id_info>
    <org_study_id>KIROVAX-003</org_study_id>
    <nct_id>NCT02224599</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies</brief_title>
  <official_title>Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Imiquimod, in Patients With Progressive and/or Refractory Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiromic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiromic, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with progressive and/or refractory solid malignancies, who have failed
      conventional therapy, and have no available, potentially curative therapeutic options, will
      be candidates for this Phase I/II study. Following confirmation of disease progression and/or
      refractoriness, eligible patients who agree to participate and sign an informed consent form
      will have their tumor cells/tissues and/or blood analyzed for the expression of a specific
      panel of Tumor Associated Peptide Antigens (TAPAs), including Sp17, ropporin, AKAP-4, PTTG1,
      Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients whose tumors express one (1) or more of these TAPAs (Sp17, ropporin, AKAP-4,
      PTTG1, Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1), whole blood will be obtained by
      phlebotomy and/or leukapheresis performed for generation of autologous DCs. Patient's DCs
      will be generated in Kiromic's Cell Processing GMP facility, according to established
      Standard Operating Procedures, and activated by pulsing/loading them with the TAPA(s)
      relevant for each particular patient. Patients will receive five (5) days of low-dose
      cyclophosphamide 5 to 7 days prior to each vaccination with TAPA-pulsed DCs to decrease Treg
      activity. Patients will also receive a single dose of topical Imiquimod cream after each
      vaccination. TAPA-pulsed DCs will be administered at a fixed dose of up to 1 X 107 DCs. DC
      vaccination schedule will be weekly via intradermal (ID) injections for a total of 3
      vaccinations. Topical Imiquimod cream will also be administered once after the vaccination.
      Patients will be followed on a weekly basis (or more frequently if required) to evaluate
      treatment-related toxicity. Immune efficacy and anti-tumor responses will be evaluated per
      protocol specifications. Continuation and stopping rules for the study will be defined based
      on toxicity/tolerability (Phase I) and immune efficacy (Phase II).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to terminate study due to poor accrual
  </why_stopped>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events Due to Administration of TAPA-Pulse DC Vaccine</measure>
    <time_frame>Continuous for 45 days after the first dose.</time_frame>
    <description>Grade, causality, start/stop dates (duration), resolutions for adverse events will be monitored and recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Days -7, 22 and 45</time_frame>
    <description>The response of T-cells present in the peripheral blood mononuclear cells (PBMCs) population to the peptides used to pulse a patient's dendritic cell vaccine is evaluated by measuring the expression of Th1/CTL-type cytokines (IFN-γ and/or TNF-α and/or IL-17) by a standard ELI-Spot assay using 500,000 PBMCs per experimental replicate and a minimum of 3 experimental replicates for each stimulation. The results are expressed as the average number of spots obtained from the stimulation of 500,000 PBMCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive DTH Skin Tests With Relevant TAPA</measure>
    <time_frame>Days -7, 22 and 45</time_frame>
    <description>DTH skin test will be performed on subject's forearm or within 5 cm from the site of prior DC vaccination, if possible</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Progressive Solid Malignancies</condition>
  <condition>Refractory Solid Malignancies</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>CYP, TAPA-pulsed DC vaccine, Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TAPA-pulsed DC vaccine</intervention_name>
    <description>Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.</description>
    <arm_group_label>CYP, TAPA-pulsed DC vaccine, Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide Pill</intervention_name>
    <description>Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.</description>
    <arm_group_label>CYP, TAPA-pulsed DC vaccine, Imiquimod</arm_group_label>
    <other_name>Cytoxan®, Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod Topical Cream</intervention_name>
    <description>Topical Imiquimod Cream will be applied after vaccination.</description>
    <arm_group_label>CYP, TAPA-pulsed DC vaccine, Imiquimod</arm_group_label>
    <other_name>Aldara Cream, Zyclara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to provide informed consent.

          2. Patients with histologically proven progressive and/or refractory SM, s/p conventional
             salvage therapy, completed at least 3 weeks prior to study vaccination, will be
             eligible for enrollment.

          3. Expression of one (1) or more of the following TAPAs: Sp17, AKAP-4, Ropporin, PTTG-1,
             Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1, by either RT-PCR and/or
             immunocytochemistry, Western blotting or ELISA, in neoplastic cells and/or blood. For
             HER-2/neu expression, positive FISH results are acceptable.

          4. Presence of measurable or evaluable disease.

          5. Patients must not have any active infectious process.

          6. Patients must not have a history of HIV, or active Hepatitis A, B, and C.

          7. Patients must not be receiving active immunosuppressive therapy.

          8. Patients must have discontinued systemic cytotoxic or radiation therapy at least three
             (3) weeks prior to vaccination and toxicities from previous therapies must be grade 1
             or less. all other FDA approved forms of antineoplastic therapy are allowed such as
             immunotherapy, targeted therapies, or hormonal therapies (67, 68)

          9. Patients may not have any known allergy to CYP and/or Imiquimod.

         10. Patients must be willing to provide at least 250 mL, and up to 500 mL, of whole blood
             obtained by phlebotomy and/or consent to leukapheresis for DC generation.

         11. Adequate renal and hepatic function (creatinine ≤ 2.0 mg/dl, bilirubin ≤ 2.0 mg/dl,
             AST and ALT ≤ 4X upper limit of normal range).

         12. Adequate hematologic function (Platelets ≥ 60,000/mm3, lymphocytes ≥ 1,000 mm3,
             neutrophils ≥ 750/mm3, hemoglobin ≥ 9.0 g/dl).

         13. Karnofsky performance status ≥ 70%.

         14. Expected survival ≥ 6 months.

         15. Either a female or male of reproductive capacity wishing to participate in this study
             must be using, or agree to use, one or more types of birth control during the entire
             study and for 3 months after completing the study. Birth control methods may include
             condoms, diaphragms, birth control pills, spermicidal gels or foams, anti-gonadotropin
             injections, intrauterine devices (IUD), surgical sterilization, or subcutaneous
             implants. Another choice is for a subject's sexual partner to use one of these birth
             control methods. Women of reproductive capacity will be required to undergo a urine
             pregnancy test before completion of the post-screening informed consent process.

        Exclusion Criteria:

          1. Patients without confirmed progressive and/or refractory SM using standard RECIST
             criteria.

          2. Patients without measurable or evaluable disease.

          3. Patients receiving cytotoxic therapy or radiation therapy, within three (3) weeks of
             vaccination.

          4. Active immunosuppressive therapy, including non-physiologic systemic steroids
             (excluding topical, intraocular, inhaled, and intranasal steroids) for any other
             condition.

          5. Persistent fever (&gt;24 hours) documented by repeated measurement or active,
             uncontrolled infection within 4 weeks of enrollment.

          6. Active ischemic heart disease or history of myocardial infarction within six months.

          7. Active autoimmune disease, including, but not limited to, Systemic Lupus Erythematosus
             (SLE), Multiple Sclerosis (MS), Ankylosing Spondylitis (AS), Inflammatory Bowel
             Disease (IBD) and Rheumatoid Arthritis (RA).

          8. Pregnancy or breast feeding.

          9. Active second invasive malignancy, other than basal cell carcinoma of the skin.

         10. Life expectancy of less than 6 months.

         11. Patients with contraindications to CYP and/or Imiquimod.

         12. Patients who have received organ transplants.

         13. Patients with psychological or geographic conditions that prevent adequate follow- up
             or compliance with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Tolcher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NEXT Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>March 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 15, 2020</results_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>TAPA-Pulsed Dendritic Cell Therapy</keyword>
  <keyword>Dendritic Cell Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02224599/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02224599/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CYP, TAPA-pulsed DC Vaccine, Imiquimod</title>
          <description>TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
TAPA-pulsed DC vaccine: Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
Cyclophosphamide Pill: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Imiquimod Topical Cream: Topical Imiquimod Cream will be applied after vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CYP, TAPA-pulsed DC Vaccine, Imiquimod</title>
          <description>TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
TAPA-pulsed DC vaccine: Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
Cyclophosphamide Pill: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Imiquimod Topical Cream: Topical Imiquimod Cream will be applied after vaccination.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.33" spread="18.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events Due to Administration of TAPA-Pulse DC Vaccine</title>
        <description>Grade, causality, start/stop dates (duration), resolutions for adverse events will be monitored and recorded.</description>
        <time_frame>Continuous for 45 days after the first dose.</time_frame>
        <population>Enrollment was terminated</population>
        <group_list>
          <group group_id="O1">
            <title>CYP, TAPA-pulsed DC Vaccine, Imiquimod</title>
            <description>TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
TAPA-pulsed DC vaccine: Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
Cyclophosphamide Pill: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Imiquimod Topical Cream: Topical Imiquimod Cream will be applied after vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Due to Administration of TAPA-Pulse DC Vaccine</title>
          <description>Grade, causality, start/stop dates (duration), resolutions for adverse events will be monitored and recorded.</description>
          <population>Enrollment was terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <description>The response of T-cells present in the peripheral blood mononuclear cells (PBMCs) population to the peptides used to pulse a patient's dendritic cell vaccine is evaluated by measuring the expression of Th1/CTL-type cytokines (IFN-γ and/or TNF-α and/or IL-17) by a standard ELI-Spot assay using 500,000 PBMCs per experimental replicate and a minimum of 3 experimental replicates for each stimulation. The results are expressed as the average number of spots obtained from the stimulation of 500,000 PBMCs</description>
        <time_frame>Days -7, 22 and 45</time_frame>
        <population>Enrollment was teriminated.</population>
        <group_list>
          <group group_id="O1">
            <title>CYP, TAPA-pulsed DC Vaccine, Imiquimod</title>
            <description>TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
TAPA-pulsed DC vaccine: Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
Cyclophosphamide Pill: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Imiquimod Topical Cream: Topical Imiquimod Cream will be applied after vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <description>The response of T-cells present in the peripheral blood mononuclear cells (PBMCs) population to the peptides used to pulse a patient's dendritic cell vaccine is evaluated by measuring the expression of Th1/CTL-type cytokines (IFN-γ and/or TNF-α and/or IL-17) by a standard ELI-Spot assay using 500,000 PBMCs per experimental replicate and a minimum of 3 experimental replicates for each stimulation. The results are expressed as the average number of spots obtained from the stimulation of 500,000 PBMCs</description>
          <population>Enrollment was teriminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive DTH Skin Tests With Relevant TAPA</title>
        <description>DTH skin test will be performed on subject's forearm or within 5 cm from the site of prior DC vaccination, if possible</description>
        <time_frame>Days -7, 22 and 45</time_frame>
        <population>Enrollment was terminated</population>
        <group_list>
          <group group_id="O1">
            <title>CYP, TAPA-pulsed DC Vaccine, Imiquimod</title>
            <description>TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
TAPA-pulsed DC vaccine: Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
Cyclophosphamide Pill: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Imiquimod Topical Cream: Topical Imiquimod Cream will be applied after vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive DTH Skin Tests With Relevant TAPA</title>
          <description>DTH skin test will be performed on subject's forearm or within 5 cm from the site of prior DC vaccination, if possible</description>
          <population>Enrollment was terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months</time_frame>
      <desc>Enrollment was terminated</desc>
      <group_list>
        <group group_id="E1">
          <title>CYP, TAPA-pulsed DC Vaccine, Imiquimod</title>
          <description>TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
TAPA-pulsed DC vaccine: Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
Cyclophosphamide Pill: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Imiquimod Topical Cream: Topical Imiquimod Cream will be applied after vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CMO and Head of Clinical Operations</name_or_title>
      <organization>Kiromic</organization>
      <phone>(832) 968-4888</phone>
      <email>sdahlbeck@kiromic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

